Bronchitis - Pipeline Review, H2 2011

Global Markets Direct, September 2011, Pages: 47

Bronchitis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Bronchitis - Pipeline Review, H2 2011', provides an overview of the Bronchitis therapeutic pipeline. This report provides information on the therapeutic development for Bronchitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bronchitis. 'Bronchitis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bronchitis.
- A review of the Bronchitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bronchitis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bronchitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bronchitis pipeline depth and focus of Bronchitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bronchitis Overview
Therapeutics Development
An Overview of Pipeline Products for Bronchitis
Bronchitis Therapeutics under Development by Companies
Bronchitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Bronchitis Therapeutics - Products under Development by Companies
Bronchitis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Bronchitis Therapeutics Development
GlaxoSmithKline plc
Cytokinetics, Inc
Ahn-Gook Pharmaceutical Co., Ltd.
SCOLR Pharma, Inc.
NanoBio Corporation
iNova Pharmaceuticals (Australia) Pty Limited
Beech Tree Labs, Inc.
Bronchitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Phenylephrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AG1321001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erdosteine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CK-2018571 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK233705 + GW642444 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AG NPP709 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CK-2019165 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Respiratory Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Chronic Bronchitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antofloxacin Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bronchitis Therapeutics - Discontinued Products
Bronchitis - Featured News
Oct 01, 2008: Pharmaxis Files First Marketing Application For Bronchitol In Australia
Aug 20, 2008: 12 Month Phase 3 Trial Finds Bronchitol Safe In Bronchiectasis
Jul 05, 2007: Pharmaxis Completes Phase III Bronchiectasis Trial
Apr 11, 2007: Pharmaxis Begins Phase III Cystic Fibrosis Trial
Feb 06, 2006: Pharmaxis Commences Operations In Europe
Jul 20, 2005: US FDA Grants Bronchitol Orphan Drug Status For Treatment Of Cystic Fibrosis
Sep 27, 2004: Pharmaxis Announces Positive Results From Phase II Trial Of Bronchitol
Nov 18, 2002: Inspire Pharmaceuticals Provides Update On INS365's Chronic Bronchitis Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Bronchitis, H2 2011
Products under Development for Bronchitis – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
GlaxoSmithKline plc, H2 2011
Cytokinetics, Inc, H2 2011
Ahn-Gook Pharmaceutical Co., Ltd., H2 2011
SCOLR Pharma, Inc., H2 2011
NanoBio Corporation, H2 2011
iNova Pharmaceuticals (Australia) Pty Limited, H2 2011
Beech Tree Labs, Inc., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Discontinued Products

List of Figures
Number of Products under Development for Bronchitis, H2 2011
Products under Development for Bronchitis – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Chronic Bronchitis - Pipeline Review, H2 2012
• Bronchitis - Pipeline Review, H2 2012
• Chronic Bronchitis - Pipeline Review, H1 2013
• Bronchitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
• Bronchitis Global Clinical Trials Review, H2, 2012
• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Obstructive Pulmonary Disease - Pipeline Review, H2 2012
• Allergic Asthma - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012